Biomarkers /
RAC1
Overview
Ras-related C3 botulinum toxin substrate 1 (RAC1) is a small GTP binding gene of the Rho family that encodes a GTPase/small GTP-binding protein of the RAS superfamily. Frameshift mutations, missense mutations, and silent mutations are observed in cancers such as breast cancer and skin cancer.
RAC1 is altered in 0.98% of all cancers with lung adenocarcinoma, cutaneous melanoma, colon adenocarcinoma, melanoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].
The most common alterations in RAC1 are RAC1 Amplification (0.43%), RAC1 P29S (0.18%), RAC1 Loss (0.03%), RAC1 P29T (0.03%), and RAC1 A159V (0.02%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.